CompletedPhase 3ACTRN12607000301460
The effects of nebulised N-acetylcysteine on sputum quality and diagnostic yield: a randomised, controlled clinical trial
A randomised clinical trial to compare the efficacy of nebulized N-acetylcysteine and normal saline in improving sputum quality and diagnostic yield in patients with chest infections.
Sponsor
Austin Health
Enrollment
190 participants
Start Date
Aug 1, 2007
Study Type
Interventional
Conditions
Summary
We believe that the use of N-acetylcysteine (a known mucolytic) will be useful in improving the diagnostic yield of sputum culture. If this hypothesis is proven, this agent can be recommend for this purpose.
Eligibility
Sex: Both males and femalesMin Age: 18 Yearss
Inclusion Criteria1
- Differential diagnosis inclusive of lower respiratory tract infection as determined by the treating physician (eg. cough, fever, pleuritic chest pain, dyspnoea, decreased breath sounds, bronchial breath sounds, crackles on auscultation) ·A sputum sample is to be collected in the ED.
Exclusion Criteria1
- Inability to co-operate or consent due to debility, significant illness, language barriers, altered consciousness (as determined by the ED or study staff)·Refusal to participate·Pregnancy or breast-feeding·Known allergy to NAC·Presence of significant hepatic or renal failure·Presence of other significant co-morbidities eg. HIV, immunocompromised, cystic fibrosis, bronchiectasis·CXR suggestive of TB·Recent hospital admission within the previous 14 days inclusively·Current treatment with >10mg prenisolone daily for more than 1 month inclusively
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose of 5 ml (200mg/ml) of nebulized N-acetylcysteine (intervention).
Single dose of 5 ml (200mg/ml) of nebulized N-acetylcysteine (intervention).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12607000301460